At a median follow-up time of 6.1 years, among patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, Lynparza reduced the risk of death by 28% compared to placebo (HR=0.72; 95% CI: 0.56-0.93). In addition, 87.5% of patients receiving Lynparza treatment were still alive, compared to 83.2% in the placebo group.
At a median follow-up time of 6.1 years, among patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, Lynparza reduced the risk of death by 28% compared to placebo (HR=0.72; 95% CI: 0.56-0.93). In addition, 87.5% of patients receiving Lynparza treatment were still alive, compared to 83.2% in the placebo group.
Lynparza is a "first in class" PARP inhibitor and the first synthetic lethal targeted therapy drug used to target cells/tumors with homologous recombination repair (HRR) defects, such as those carrying BRCA1 and/or BRCA2 mutations. Based on the results of Phase III clinical trial OlympiA, Lynparza has been approved in the United States, the European Union, Japan and many other countries and regions for the treatment of gBRCAm, HER2 negative high-risk early breast cancer. In addition, it has been approved to treat gBRCAm, HER2 negative metastatic breast cancer in the United States, the European Union, Japan and many other countries and regions.
<Reprinted from WuXi AppTec>







